The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive
Su Yu,1,2 Yang Zhang,1 Yunjian Pan,1 Chao Cheng,1,3 Yihua Sun,1,3 Haiquan Chen1–4 1Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; 2Cancer Research Center, Fudan University Shanghai Cancer Center, Shanghai, China; 3Department of Oncology, Shanghai...
Main Authors: | Yu S, Zhang Y, Pan YJ, Cheng C, Sun YH, Chen HQ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-09-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/the-non-small-cell-lung-cancer-egfr-extracellular-domain-mutation-m277-peer-reviewed-article-OTT |
Similar Items
-
Effect of EGFR-TKI on Lymphangiogenesis of Lung Cancer with EGFR Mutation
by: Minghui CAI, et al.
Published: (2014-12-01) -
Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
by: Eun Young Kim, et al.
Published: (2018-12-01) -
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
by: Diego Enrico, MD, et al.
Published: (2020-06-01) -
Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer
by: Vinh Thanh Tran, et al.
Published: (2020-08-01) -
Oncogenic mutations within the β3‐αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies
by: Biao Zhang, et al.
Published: (2020-10-01)